Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

RSS icon
heart patient

TEER safe and feasible for patients with atrial secondary mitral regurgitation

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates. 

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

The Abbott Cephea transcatheter mitral valve replacement (TMVR) system.

Cardiologist praises updated design of new TMVR system after historic interventional procedure

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.

Risk of death increases when TEER patients present with hypertrophic cardiomyopathy

A team of Cleveland Clinic researchers tracked data from nearly 23,000 patients, sharing their findings in the American Journal of Cardiology. 

Mitral annular calcium (MAC) does not appear to have a negative effect on long-term transcatheter aortic valve replacement (TAVR) outcomes, according to new research published in the American Journal of Cardiology.

TAVR safe and effective for patients presenting with mitral annular calcium

Researchers from Cleveland Clinic reviewed data from more than 400 patients, presenting their findings in the American Journal of Cardiology.

Performing valve-in-valve transcatheter mitral valve replacement (ViV TMVR) with conscious sedation (CS) or monitored anesthesia care (MAC) instead of general anesthesia (GA) is safe and effective, according to new research published in JACC: Cardiovascular Interventions.

Using a TAVR-like minimalist approach for valve-in-valve TMVR is safe and effective, Cleveland Clinic study confirms

During valve-in-valve TMVR, patients are treated with conscious sedation or monitored anesthesia care instead of general anesthesia. This new analysis confirms that the change does not impact patient outcomes, but it was linked to a shorter length of stay.

Cardiothoracic surgeons perform UCSF's first robotic mitral valve surgery. A 3D camera allows surgeons to see the mitral valve and other structures inside the heart. Surgeons use a robotic surgical system to guide the robotic arms and movements of the surgical instruments.

Surgeons praise mobility, precision of robotically assisted mitral valve procedure

“Robotically assisted mitral valve surgery allows us to make even smaller incisions with greater precision,” one surgeon said. “By using the robotic arms, we have more degrees of articulation than with our natural wrists."

Mitral and_tricuspid transcatheter valves Evoque and Intrepid were discussed at TVT 2022.

VIDEO: Advances in transcatheter tricuspid and mitral valve technology

Anita W. Asgar, MD, director, transcatheter valve therapy research at Montréal Heart Institute, discusses advances and new technology for mitral and tricuspid valves at the 2022 Transcatheter Valve Therapies (TVT) meeting. 

Displaying 57 - 64 of 110
Design by Adaptive Theme